Abstract
Background
CYP2D6 is an important cytochrome P450 enzyme. These enzymes catalyse the oxidative biotransformation of about 25% of clinically important drugs as well as the metabolism of numerous environmental chemical carcinogens. The most frequent null allele of CYP2D6 in European populations, CYP2D6*4, has been studied here in order to elucidate whether a relationship exists between this allele and the risk of developing breast cancer in a Spanish population.
Materials and methods
Ninety-six breast cancer Spanish patients and one hundred healthy female volunteers were genotyped for the CYP2D6*4 allele using AmpliChip CYP450 Test technology.
Results
Homozygous CYP2D6*4 frequency was significant lower in breast cancer patients than in the control group (OR=0.22, p=0.04). The heterozygous CYP2D6*4 group also displayed lower values in patients than in controls but the difference was not significant (OR=0.698, p=0.28). Therefore, the presence of the CYP2D6*4 allele seems to decrease susceptibility to breast carcinoma in the selected population.
Conclusions
A possible decreased transformation of procarcinogens by CYP2D6*4 poor metabolisers could result in a protective effect against carcinogens.
Article PDF
Avoid common mistakes on your manuscript.
References
Han W, Kang D, Park IA et al (2004) Associations between breast cancer susceptibility gene polymorphisms and clinical pathological features. Clin Cancer Res 10:124–139
Chacko P, Joseph T, Mathew BS et al (2005) Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome. Mut Res 581:153–163
Bonanni B, Macis D, Maisonneuve P et al (2006) Polymorphism in the CYP2D6 tamoxifen-metabolizing gene infl uences clinical effect but not hot fl ashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24:3708–3709
Sistonen J, Fuselli S, Palo JU et al (2009) Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 9:170–179
Ingelman-Sundberg M, Sim SC (2010) Intronic polymorphisms of cytochromes P450. Hum Genomics 4:402–405
Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6–13
Dunning AM, Healey CS, Pharoah PDP et al (1999) A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev 8:843–854
Arvanitidis K, Ragia G, Iordanidou M et al (2007) Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 21:419–426
Buzkova H, Pechandova K, Slanar O, Perlik F (2008) Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population. Cell Biochem Funct 26:76–81
Sistonen J, Sajantila A, Lao O et al (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17: 93–101
Ladona MG, Abildua RE, Ladero JM et al (1996) CYP2D6 genotypes in Spanish women with breast cancer. Cancer Lett 99:23–28
Ayesh R, Idle JR, Ritchie JC et al (1984) Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 312:169–170
Khedhaier A, Hassen E, Bouaouina N et al (2008) Implication of xenobiotic metabolizing enzyme gene (CYP2E1, CYP2C19, CYP2D6, Meh and NAT2) polymorphisms in breast carcinoma. BMC Cancer 8:109
Torresan C, Oliveira MMC, Torrezan GT et al (2008) Genetic polymorphisms in oestrogen metabolic pathway and breast cancer: a positive association with combined CYP/GST genotypes. Clin Exp Med 8:65–71
Li H, Feng L, Yao L et al (2006) The association of CYP2D6*10 polymorphism with breast cancer risk and clinic-pathologic characteristics in Chinese women. Acta Oncol 45:597–601
Lemos MC, Carrilho F, Rodrigues F et al (2007) Genetic polymorphism of CYP2D6 influences susceptibility to papillary thyroid cancer. Clin Endocrinol (Oxf) 67:180–183
Rostami-Hodjegan A, Lennard MS, Woods HF, Tucker GT (1998) Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson’s disease. Pharmacogenetics 8:227–238
Ouerhani S, Marrakchi R, Bouhaha R et al (2008) The role of CYP2D6*4 variant in bladder cancer susceptibility in Tunisian patients. Bull Cancer 95:E1–4
Luo YP, Chen HC, Khan MA et al (2011) Genetic polymorphisms of metabolic enzymes-CYP1A1, CYP2D6, GSTM1, and GSTT1, and gastric carcinoma susceptibility. Tumour Biol 32:215–222
Agundez JA, Ledesma MC, Benitez J et al (1995) CYP2D6 genes and risk of liver cancer. Lancet 345:830–831
Yadav SS, Ruwali M, Pant MC et al (2010) Interaction of drug metabolizing cytochrome P450 2D6 poor metabolizers with cytochrome P450 2C9 and 2C19 genotypes modify the susceptibility to head and neck cancer and treatment response. Mutat Res 684:49–55
Strange RC, Ellison T, Ichii-Jones F et al (1999) Cytochrome P450 CYP2D6 genotypes: association with hair colour, Breslow thickness and melanocyte stimulating hormone receptor alleles in patients with malignant melanoma. Pharmacogenetics 9:269–276
Gomes L, Lemos MC, Paiva I et al (2005) CYP2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port 18:339–343
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fernández-Santander, A., del Saz Sánchez, M., Tejerina Gómez, A. et al. CYP2D6*4 allele and breast cancer risk: Is there any association?. Clin Transl Oncol 14, 157–159 (2012). https://doi.org/10.1007/s12094-012-0776-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0776-4